AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 22 min read$EBS

Williams Paul Anthony sold $25K of EBS

Williams Paul Anthony (SVP, Products Business) sold 3,000 shares of Emergent BioSolutions Inc. (EBS) at $8.40 on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Williams Paul Anthony
Published Jul 2, 2026, 4:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 5:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$EBS
Neutral
high confidence
Mentioned
$EBS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EBSNeutralLow
01

Why it matters

This is a scheduled open-market sale by an SVP under a Rule 10b5-1 plan; it is more useful for monitoring insider activity than for forecasting near-term earnings or guidance.

02

Market read

Traders may note the insider sale for sentiment/positioning, but there is no new company-specific fundamental information.

03

What to watch

The disclosure does not indicate why shares were sold (taxes, diversification, scheduled plan), so any bearish interpretation is likely overstated without additional corroboration.

Relevance 2/10Novelty 3/10Timing: SEC Form 4 filed 2026-07-02; sale executed 2026-07-01

Background

The article is an SEC Form 4 insider transaction disclosure for Emergent BioSolutions Inc. (EBS).

Company-level read

Ticker impact

$EBSNeutralHigh confidence
Context

SEC Form 4 shows Emergent BioSolutions SVP Paul Anthony Williams sold 3,000 shares at $8.40 on 2026-07-01 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this disclosure.

Evidence & confidence

The filing is an open-market sale by an officer, explicitly under a pre-arranged 10b5-1 plan, with no accompanying operational or financial guidance changes.

Market effects

Sector

No clear read-across to biotech sector fundamentals from a single officer 10b5-1 sale.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can coincide with internal caution; traders may watch for follow-on sales or changes in selling patterns.

Key entities

  • public_company
    Emergent BioSolutions Inc.

    Issuer of the Form 4 insider transaction; SVP Paul Anthony Williams sold shares under a 10b5-1 plan.

  • insider
    Paul Anthony Williams

    SVP, Products Business; reported open-market sale of 3,000 shares at $8.40 on 2026-07-01.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EBS insider trading history →

Related articles

AUG 18
$EBSMedAI 8/10

S&P downgrades Emergent BioSolutions outlook on competition

S&P Global Ratings revised Emergent BioSolutions' outlook to negative, citing lower revenue guidance due to competition in the naloxone market. The company reduced its 2026 revenue and EBITDA guidance by $80M and $25M, respectively, due to weaker NARCAN sales. S&P noted potential refinancing risks for Emergent's $440M unsecured notes maturing in 2028, with declining revenue and uncertain growth prospects.

investing.com4 min
AUG 9
$EBSHighAI 9/10

Emergent Biosolutions Q2 Earnings Call Highlights

Emergent BioSolutions (EBS) reported Q2 updates on its MCM and naloxone franchises. Management said MCM international sales were about 20% of first-half 2026 revenue. It received regulators’ approvals to expand ACAM2000 to Mpox. Due to NARCAN competition, EBS lowered 2026 revenue guidance to $645M-$675M and recorded a ~$191M non-cash impairment, plus ~$40M annualized cost savings.

yahoo.com6 min
AUG 7
$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

rttnews.com7 min
AUG 7
$EBSMedAI 8/10

Emergent BioSolutions Q2 Revenue Jumps, Net Loss Widens Amid Restructuring

Emergent BioSolutions (EBS) reported Q2 2026 revenue of $234.3 million, up 66% year over year, driven by accelerated U.S. government MCM contract modifications. Net loss widened to $180.2 million due to a $191.3 million non-cash Naloxone impairment. Adjusted EBITDA rose to $96.5 million. The company cut 2026 guidance and announced restructuring, including wet lab closures and about 93 job reductions.

rttnews.com5 min
AUG 5
$EBSMed

Emergent BioSolutions Inc. (EBS): Results of Operations and Financial Condition

Emergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS • Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior year • Second Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million

SEC EDGAR 8-K6 min